Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dissect a pair of disappointing clinical results from newfangled ideas in biotech, discussing what each means — and doesn’t mean — for the future. Then, blogger Derek Lowe joins us to talk about his disagreement with Rep. Alexandria Ocasio-Cortez on the relationship between publicly funded research and industry-marketed drugs, a conversation that touches on science, policy, and sexism. Finally, STAT Washington correspondent Lev Facher calls in to discuss the slate of candidates lined up to challenge President Trump in 2020 and the ideas they bring to the world of drug pricing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy